Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Xiaoying Zhao, Zhiyu Chen, Chen Chen Wang et al.|Journal of Clinical Oncology|2017

Cited by 0